Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bibrocathol-POS 2% for chronic blepharoconjunctivitis
ISRCTN14084351Phase 3Completed
- Sponsor
- URSAPHARM
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of bibrocathol in Chronic blepharoconjunctivitis (2 arms), sponsored by URSAPHARM. Primary endpoint: Sum score of signs of chronic blepharoconjunctivitis. Started Jan 2018; status: completed.
02
Drugs
bibrocathol
03
Conditions
Chronic blepharoconjunctivitis
Beyond the preview
Go deeper on ISRCTN14084351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN14084351.